Mechanisms Regulating Cytomegalovirus
Mechanisms Regulating Cytomegalovirus
批准号:
10481050
负责人:
JEFFERY L MEIER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-10-01 至 2026-09-30
关键词:
AcuteAddressAffectAntiviral AgentsBindingBiological AssayCell LineCell modelChIP-seqChromatinChromatin StructureCollaborationsComplexCongenital AbnormalityCost SavingsCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesDNA Polymerase IIDNA SequenceDNA biosynthesisDataDiseaseDrug resistanceEnvironmentFibroblastsGene ExpressionGene Expression RegulationGenesGenetic EngineeringGenetic TranscriptionGenomeGenomic approachGoalsHealthHealth Care CostsHerpesviridaeHourHumanHuman Herpesvirus 4Human Herpesvirus 6Immune systemImpairmentIndividualInfectionInfection preventionInflammationInstitute of Medicine (U.S.)KnowledgeLifeMapsMass Spectrum AnalysisModelingNucleosomesOncogenicOutputPathway interactionsPatternPopulationPredispositionPriceProductivityPromoter RegionsProtein IsoformsRegulationResearchResolutionRoleSignal TransductionSiteSystemTaxesTechniquesTechnologyTestingTherapeuticTherapeutic InterventionToxic effectTranscriptTranscription InitiationVeteransViralViral Drug ResistanceVirusVirus ActivationVirus Diseasesbioinformatics pipelinecell typedesignfunctional genomicsgammaherpesvirusgenetically modified cellsgenome-widegenomic locushuman diseasehuman modelmembermortality risknew therapeutic targetnovel therapeuticspharmacologicpreventprogramspromotersarcomatooltranscription factorviral DNAvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Human cytomegalovirus (HCMV) infects over half of all Veterans and threatens the lives of those with
impaired immune systems. HCMV is the leading infectious cause of birth defects. There is no HCMV
vaccine, and the antiviral drugs have problems with potency, toxicity, and drug-resistance. The long-range
goal of this research is to identify critical points in the viral transcription-DNA replication cycle that would
serve as new targets for therapeutic intervention. This proposal is based on the premise that our gap in
knowledge of how viral early transcription produces viral DNA replication and how viral DNA replication
results in viral late transcription limits our ability to design new therapeutic treatments for the viral disease.
By customizing advanced technologies and developing new tools, we have used integrated functional
genomics (dTag system, PRO-Seq, ChIP-Seq, genetically engineered test viruses, and promoter function
assays) to determine where and when Pol II initiates transcription, identify sites of viral transcription factor
binding genome-wide, and quantify change in Pol II nascent transcripts from individual promoters in relation
to core promoter sequences, transcription factor loss, stage of infection, and viral DNA replication. We find
that there are three distinct pathways to viral late transcription. Two of these pathways involve the HCMV
IE2 and late transcription factor (LTF) group members. The individual role of each of the 3 different IE2
isoforms (IE2-86, IE2-60, and IE2-40) in viral late transcription is unknown. The six-member set of LTFs
bind to Pol II and a DNA sequence signature in gene promoters, forming a preinitiation complex (PIC) that
drives transcription. Diversity in sequence signature pattern likely determines the amount of individual
promoter output. It is unknown precisely when and how the LTF complex assembles on viral promoters and
how the LTF assembly engages Pol II in transcription. Our use of a new high-resolution ChIP-Seq technique
and bioinformatics pipeline to map genomic locations of nucleosomes, as well as IE2 and LTF PICs,
suggests that LTF PICs occupy genome regions not occupied by nucleosomes. This new ChIP-Seq
technique will strengthen our integrated functional genomics approach to further determining the
mechanisms controlling viral promoter transcription in relation to chromatin structure. Our preliminary data
indicate that: 1) the early-late transcription switch lags many hours behind the onset of viral DNA replication;
2) the HCMV promoter population members that are active differs by cell type and condition, and this
difference may involve IE2 and LTF functions; and 3) the HCMV promoter population that is active during
viral reactivation in the NT2 model differs from that in acute productive infection. We will test the hypothesis
that HCMV transcription factors usurp host Pol II that navigates a modified chromatin environment suited to
bring about viral late transcription (Aims 1 and 2) and to coordinate the viral transcription program in diverse
cell types (Aim 2) and under cellular conditions supporting quiescent and reactivation infections in the NT2
model (Aim 3). We will apply a multifaceted approach to each of the specific aims to: 1) elucidate the
regulators of the early-late transcription switch, 2) determine the mechanistic basis for cell type differences
in viral transcription, and 3) determine how activation of quiescent infection changes viral transcription. Our
proposal integrates the expertise of the Meier and the Price labs in virology and transcription, respectively.
We will build on this productive collaboration to complete the proposed research plan. The discoveries
coming from these studies will identify generalizable features of gene regulation that pertain to other
members of beta- and gammaherpesvirus subfamilies, which include human herpesvirus 6 and the
oncogenic herpesviruses, Epstein-Barr Virus and Kaposis sarcoma-associated herpesvirus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms regulating cytomegalovirus
-
批准号:10421243
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:JEFFERY L MEIER
-
依托单位:
Mechanisms regulating cytomegalovirus
-
批准号:10047701
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:JEFFERY L MEIER
-
依托单位:
Control of Human Cytomegalovirus
-
批准号:8413400
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JEFFERY L MEIER
-
依托单位:
Control of Human Cytomegalovirus
-
批准号:8762410
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JEFFERY L MEIER
-
依托单位:
Control of Human Cytomegalovirus
-
批准号:8243763
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JEFFERY L MEIER
-
依托单位:
Control of Human Cytomegalovirus
-
批准号:8598021
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION
-
批准号:7604851
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2007
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5211 HIV-1 ENTRY INHIBITOR, SCH 417690, TO TREAT HIV INFECTED SUBJECTS
-
批准号:7604836
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2007
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5001 - AIDS LONGITUDINAL LINKED RANDOMIZED TRIALS
-
批准号:7604800
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2007
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5202 & ACTG A5224S EMTRICITABINE/TENOFOVIR OR ABACAVIR/LAMIVUDINE FOR HIV
-
批准号:7604863
-
项目类别:
-
资助金额:$0.48万
-
财政年份:2007
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION
-
批准号:7377066
-
项目类别:
-
资助金额:$1.25万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5095 THREE PROTEASE INHIBITOR-SPARING REGIMENS IN HIV PATIENTS
-
批准号:7376984
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5001 - AIDS LONGITUDINAL LINKED RANDOMIZED TRIALS
-
批准号:7376979
-
项目类别:
-
资助金额:$2.26万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5142 - PHASE III DRUG THERAPY FOR HIV-1 INFECTION
-
批准号:7377007
-
项目类别:
-
资助金额:$1.33万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5030 VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV
-
批准号:7377018
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5211 HIV-1 ENTRY INHIBITOR, SCH 417690, TO TREAT HIV INFECTED SUBJECTS
-
批准号:7377046
-
项目类别:
-
资助金额:$2.42万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5186 FISH OIL AND FENOFIBRATE IN SUBJECTS ON HAART
-
批准号:7377028
-
项目类别:
-
资助金额:$0.47万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5202 & ACTG A5224S EMTRICITABINE/TENOFOVIR OR ABACAVIR/LAMIVUDINE FOR HIV
-
批准号:7377083
-
项目类别:
-
资助金额:$1.56万
-
财政年份:2006
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5174/A5198S IMPROVING IMMUNE RECONSTITUTION WITH GROWTH HORMONE IN HIV
-
批准号:7201343
-
项目类别:
-
资助金额:$0.63万
-
财政年份:2005
-
负责人:JEFFERY L MEIER
-
依托单位:
ACTG A5186 FISH OIL AND FENOFIBRATE IN SUBJECTS ON HAART
-
批准号:7201361
-
项目类别:
-
资助金额:$1.89万
-
财政年份:2005
-
负责人:JEFFERY L MEIER
-
依托单位:
海外基金